-+ 0.00%
-+ 0.00%
-+ 0.00%

*Psyence Group Has Significantly Reduced Its Operating Costs by No Longer Having to Fund the Clinical Trial Being Carried out by iNGEN , and by Substantially Reducing Its General and Administrative Costs, as Well as Removing the Compensation of a Number of Senior Executives and Consultants Who Will Now Be Employed by PBM >PSYG.CN.L

Dow Jones·03/11/2024 11:07:00

Please log in to view news